ABSTRACT

Background: A number of biochemical predictors of preeclampsia have been reported, but little is known about their possible relationship with maternal and fetal outcomes. This study determined serum copeptin in pregnant women with preeclampsia and assessed its relationship with pregnancy outcomes. Materials and Methods: Thirty women with severe preeclampsia (SP), 30 with mild preeclampsia (MP), and 30 with uncomplicated pregnancy were enrolled into this study. Serum copeptin, creatinine, and liver function were determined using enzyme-linked immunosorbent assay and colorimetry as appropriate. Pregnancy outcomes, both maternal and fetal, were taken using standard methods. Results: Copeptin was significantly elevated in preeclampsia subjects compared with controls and in SP compared with MP. Assessing the diagnostic property of copeptin for preeclampsia, the area under the curve for copeptin was 0.99. Nine (30%) and 3 (10%) of SP and MP, respectively had abruptio placentae while 6 (20%), 2 (6.7%), and 1 (3.3%) still births were recorded in SP, MP, and controls, respectively. Neonates of mothers with preeclampsia had significantly lower birth weight, infant length, ponderal index, and head circumference compared with neonates of the controls. Copeptin had a significant inverse relationship with birth weight, ponderal index, head circumference, Apgar score, and infant length in neonates of mothers with preeclampsia. Conclusion: Serum copeptin level in the third trimester could predict preeclampsia and its elevation is associated with adverse perinatal outcome. Key words: Abruptio placentae, Apgar score, copeptin, perinatal outcome, ponderal index, preeclampsia

INTRODUCTION

Preeclampsia is a complex pregnancy disorder that has been associated with severe maternal, fetal, and neonatal complications. It is characterized by increased blood pressure (BP), proteinuria, vasoconstriction, increased peripheral vascular resistance, and reduced organ perfusion. Usually, it is associated with primigravid patients during the last trimester.1,2 The incidence of preeclampsia varies worldwide. The World Health Organization estimated that the incidence of preeclampsia is 7 times higher in developing countries (2.8% of live births) than in developed countries (0.4%).

Preeclampsia continues to be a leading cause of maternal mortality in both developed and developing countries.3 It is associated with a five-fold increase in mortality, which can increase several folds when necessary intervention is delayed especially when it has progressed to eclampsia.4,5

Previous reports in Nigeria showed that preeclampsia and eclampsia are among the most common causes of maternal mortality. This has been attributed to poor health seeking
Preeclampsia is diagnosed with BP of >140/90 mmHg, in combination with proteinuria (300 mg/24 h or ≥1+ by dipstick) on at least 2 occasions measured at least 4 h apart. It is classified as mild by the presence of proteinuria of 1+, but without evidence of end-organ damage in the patient. However, it is classified as severe by the presence of proteinuria of more than 5 g in 24 h, or ≥3+ on 2 random urine samples. Other indicators of severe preeclampsia (SP) includes oliguria of <500 ml in 24 h, pulmonary edema or cyanosis, visual or cerebral disturbance, impaired liver function, thrombocytopenia, hyperuricemia, epigastria or right upper quadrant pain and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome.

Although age, parity, social status, race, genetic factors, twin gestation, hydatidiform mole, obesity, smoking, hydropic abortion, chronic hypertension, diabetes mellitus (DM), and chronic renal disease are among several risk factors identified for preeclampsia, the mechanism by which preeclampsia develops is still not well understood. It has been shown that abnormal placentation, oxidative stress, vasoconstriction and thickening of vascular media, reduced uteroplacental perfusion, numerous maternal immunologic intolerance, and genetics are involved in the pathogenesis of preeclampsia.

There has been intense research on reliable biological markers that could predict the onset and even the severity of preeclampsia with a view to provide early medical intervention. One of such markers that have received much attention is copeptin.

Copeptin is a peptide containing 39 amino acids. It is co-secreted (in an equimolar ratio) with arginine vasopressin (AVP) from the neurohypophysis upon hemodynamic or osmotic stimuli. Compared to AVP, copeptin is both stable in serum and plasma at room temperature and can easily be measured as AVP surrogate. Earlier reports showed that copeptin is a potent predictor of preeclampsia and may be involved in its pathogenesis. Furthermore, Santillan et al. recently showed that elevated maternal plasma copeptin is a highly significant predictor of preeclampsia as early as the 6th week of gestation. Despite these available reports on the ability of copeptin to predict possible development of preeclampsia, there is a dearth of information on its relationship with pregnancy outcomes such as abruptio placenta, maternal death, ponderal index, Apgar score, and even fetal/neonatal death in women with preeclampsia. Thus, this serves as the basis for this study.
**Blood pressure and anthropometric measurement**

Height (m) was taken using a stadiometer. Body mass index (BMI) was calculated as the ratio of prepregnancy body weight (kg) to the square of height (m²). After at least 10 min of rest, BP was obtained with the patient in supine position using a mercury sphygmomanometer. Korotkoff phases 1 and 5 were used as recommended.²

**Sample collection**

About 10 ml of venous blood was collected from each participant and dispensed into lithium heparin and plain bottles to obtain plasma and serum, which were stored at −20°C until analyzed. In addition, 5 ml of random urine (midstream) was collected for urinalysis using dip stick method. All samples were collected at recruitment.

**Assay methodology**

Serum copeptin level was measured using enzyme-linked immunosorbent assay (Glory Biosciences, USA). Levels of total protein, albumin, bilirubin, creatinine, and activities of aspartate (AST) and alanine amino transferases (ALT) were measured colorimetrically using Randox reagents (Randox Laboratories, UK).

**Statistical analysis**

Data analysis was done using SPSS, version 17.0 (IBM, Armonk, NY, USA). Comparison of variables between groups was done using one-way analysis of variance (ANOVA) followed by a post-hoc test. Prediction of the diagnostic property of copeptin was done by determining the area under the receiver operating characteristic curve while Pearson’s correlation was used to test the association between variables. The relationship between qualitative variables was determined using Fisher’s exact test. All tests were two-tailed, and $P<0.05$ was considered to be statistically significant.

**RESULTS**

The anthropometric, clinical, and biochemical parameters of the study participants are summarized in Table 1. The mean prepregnancy body weight, BMI, systolic BP (SBP), diastolic BP (DBP), mean levels of total bilirubin and copeptin, and mean activities of AST, ALT were significantly higher in women with preeclampsia compared with the controls. The mean copeptin level was more than 3 times higher in women with preeclampsia compared with the controls.

In Table 2, women with MP, SP, and controls were compared using ANOVA. It was observed that SBP, DBP, total bilirubin, copeptin, and activities of AST and ALT progressively increased from the controls through SP. Women with MP had significantly higher body weight, BMI, SBP, DBP, and copeptin level compared with controls, while body weight, BMI, SBP, DBP, mean levels of total bilirubin and copeptin, and mean activities of AST, ALT were higher in SP compared with the controls. However, SBP, DBP, mean levels of total bilirubin and copeptin, and mean activities of AST and ALT were higher in SP compared with MP.

Assessing the diagnostic property of copeptin for preeclampsia, it was observed that the area under the curve for copeptin was 0.99 ($P=0.000$) [Figure 1].

Selected outcomes are shown in Table 3. No maternal death or seizures were recorded in all the groups. None of the controls had abruptio placenta, but 9 SP and 3 MP had. In addition, 6, 2, and 1 still births were recorded in SP, MP, and controls, respectively [Table 3].

In Table 4, birth weight, infant length, Apgar score, and head circumference were significantly lower in neonates of women with preeclampsia when compared with the controls. Similarly, birth weight, infant length, Apgar score, and head circumference were significantly lower in neonates of SP compared with MP [Table 5].

In women with preeclampsia, copeptin had significant positive correlation with SBP, DBP, proteinuria, creatinine, AST, ALT, total bilirubin, and length of hospital stay [Table 6]. However, in neonates of women with preeclampsia, copeptin had significant negative correlation with birth weight, head circumference, Apgar score, infant length, and infant gestational age [Table 7].

**DISCUSSION**

Preeclampsia continues to be a major cause of maternal mortality, acute and long-term morbidities, perinatal deaths, preterm birth, and intrauterine growth restriction.³ In this study, prepregnancy body weight and BMI were elevated in women with preeclampsia compared with

**Table 1: Characteristics of the study participants**

| Parameters          | Preeclampsia (n=60) | Control (n=30) | P   |
|---------------------|---------------------|----------------|-----|
| Age (years)         | 31.08±3.26          | 30.90±3.40     | 0.810 |
| Body weight (kg)    | 68.65±11.62         | 60.00±15.06    | 0.000* |
| BMI (kg/m²)         | 26.54±3.98          | 24.00±3.70     | 0.000* |
| SBP (mmHg)          | 127.63±29.10        | 123.60±7.50    | 0.000* |
| DBP (mmHg)          | 104.30±10.00        | 77.00±5.20     | 0.000* |
| Creatinine (mg/dl)  | 0.67±0.36           | 0.60±0.20      | 0.380  |
| AST (IU/L)          | 32.0±18.89          | 20.53±7.31     | 0.010* |
| ALT (IU/L)          | 17.19±10.40         | 12.02±3.88     | 0.000* |
| Total protein (g/dl)| 5.99±0.64           | 6.06±0.72      | 0.620  |
| Albumin (g/dl)      | 3.04±0.29           | 3.11±0.48      | 0.450  |
| Total bilirubin (mg/dl) | 0.78±0.39    | 0.39±0.11     | 0.000* |
| Direct bilirubin (mg/dl) | 0.28±0.19    | 0.20±0.19     | 0.680  |
| Copeptin (pmol/L)   | 1.33±0.66           | 0.39±0.12      | 0.000* |

*Significant at $P<0.05$, results are reported as means±SD; ¹Prepregnancy body weight was obtained from 56 controls and 40 preeclampsia subjects, BMI—Body mass index; SBP—Systolic blood pressure; DBP—Diastolic blood pressure; AST—Aspartate aminotransferase; ALT—Alanine aminotransferase; SD—Standard deviation
controls. This observation is in agreement with the report of Hauger et al.,\textsuperscript{17} which showed that high prepregnancy body weight increases the risk of developing preeclampsia.

The observed elevated BP (SBP and DBP) in women with preeclampsia compared with normotensive women and in SP compared with MP is not a novel finding. Preeclampsia has been identified as a hypertensive disorder, and hypertension is an important criterion in the diagnosis of

---

**Table 2: Anthropometric, clinical, and biochemical data in women with severe and mild preeclampsia and controls**

| Parameters                  | Severe preeclampsia (n=30) | Mild preeclampsia (n=30) | Control (n=30) | P    |
|-----------------------------|----------------------------|--------------------------|----------------|------|
| Age (years)                 | 31.43±3.14                 | 30.70±3.40               | 30.90±3.40     | 0.690|
| Body weight (kg)\textsuperscript{a} | 69.1±14.97                 | 68.20±5.6               | 60.00±5.06     | 0.000|
| BMI (kg/m\textsuperscript{2}) | 26.72±3.40                | 26.36±4.57              | 24.00±1.73     | 0.160|
| SBP (mmHg)                  | 194.60±24.79\textsuperscript{1,2} | 148.70±4.71\textsuperscript{1} | 123.60±7.50    | 0.000|
| DBP (mmHg)                  | 111.0±8.85\textsuperscript{1,3} | 97.50±5.82\textsuperscript{1} | 77.00±3.20     | 0.000|
| Creatinine (mg/dl)          | 0.70±0.46                  | 0.61±0.21                | 0.60±0.20      | 0.280|
| AST (IU/L)                  | 41.40±21.90\textsuperscript{2,3} | 20.60±3.64\textsuperscript{1} | 20.33±3.71     | 0.000|
| ALT (IU/L)                  | 21.37±12.50\textsuperscript{1} | 12.23±3.81              | 12.00±3.88     | 0.000|
| Total protein (g/dl)        | 5.99±0.64                  | 6.06±0.63               | 6.07±0.78      | 0.890|
| Albumin (g/dl)              | 3.04±0.29                  | 3.10±0.49               | 3.20±0.99      | 0.740|
| Direct bilirubin (mg/dl)    | 0.98±0.36\textsuperscript{1,3} | 0.43±0.14              | 0.39±0.11      | 0.000|
| Copeptin (pmol/L)           | 1.70±0.66\textsuperscript{2,3} | 0.96±0.43\textsuperscript{1} | 0.39±0.12      | 0.000|

Significant at P<0.05, results are reported as mean±SD; \textsuperscript{a}Significantly different from control; \textsuperscript{1}Significantly different from mild preeclampsia; \textsuperscript{2}Prepregnancy body weight was obtained from 26 controls, 20 mild preeclampsia and 20 severe preeclampsia subjects. BMI – Body mass index; SBP – Systolic blood pressure; DBP – Diastolic blood pressure; AST – Aspartate aminotransferase; ALT – Alanine aminotransferase; SD – Standard deviation.

---

**Table 3: Maternal outcomes and fetal status at birth in women with preeclampsia and controls**

| Parameters             | Preeclampsia | P | Severe preeclampsia | P |
|------------------------|--------------|---|---------------------|---|
| Seizure                |              |   | 0                   |   |
| Yes                    | 0            |   | 0                   |   |
| No                     | 60           | 30| 30                  | 30|
| Maternal death         |              |   | 0                   |   |
| Yes                    | 0            |   | 0                   |   |
| No                     | 60           | 30| 30                  | 30|
| Delivery mode (%)      |              |   | 0.000*              |   |
| Vaginal                | 7 (21.2)     | 26 (78.8) | 0 (0.0) | 7 (100.0) | 0.011* |
| Caesarean section      | 53 (93.0)    | 4 (7.0) | 30 (56.6) | 23 (43.4) |
| Abruptio placenta (%)  |              |   | 0.007*              |   |
| Yes                    | 12 (100.0)   | 0 (0.0) | 9 (75.0) | 3 (25.0) | 0.104 |
| No                     | 48 (61.5)    | 30 (38.5) | 21 (43.8) | 27 (56.3) |
| Status at birth (%)    |              |   | 0.262               |   |
| Still birth            | 8 (88.9)     | 1 (11.1) | 6 (75.0) | 2 (25.0) | 0.254 |
| Alive                  | 52 (64.2)    | 29 (35.8) | 24 (46.2) | 28 (53.8) |

*Significant at P<0.05

---

**Table 4: Fetal and neonatal outcomes in women with preeclampsia and controls**

| Parameters                        | Preeclampsia (n=60) | Control (n=30) | P    |
|-----------------------------------|---------------------|----------------|------|
| Gestational age at delivery (days)| 240.20±11.28        | 268.40±6.20    | 0.000*|
| Birth weight (kg)                 | 1.81±0.50           | 3.47±0.31      | 0.000k |
| Infant length (m)                 | 0.39±0.03           | 0.47±0.01      | 0.000k |
| Ponderal index (kg/m\textsuperscript{2}) | 30.30±6.37       | 34.00±3.32     | 0.000k |
| Apgar score at 5 min              | 6.77±1.82           | 9.03±1.81      | 0.000k |
| Head circumference (cm)           | 25.11±2.70          | 35.60±0.70     | 0.000k |

*Significant at P<0.05
They showed that plasma copeptin level was higher (232.80±10.00 μg/L) in women with severe preeclampsia compared with the control group (34.0±3.32 μg/L) (P<0.000*). Severe preeclampsia and preeclampsia with features (P<0.040*) were associated with increased copeptin levels. This was also evident in mild preeclampsia (24.15±2.78 μg/L) compared with the control group (9.03±1.81 μg/L) (P<0.030*). Mild preeclampsia was also associated with elevated copeptin levels compared with the control group (26.06±2.28 μg/L) (P<0.050). These observations suggest that copeptin could be a useful biomarker in the prediction and management of preeclampsia.

In addition, the observed elevated serum copeptin level in women with preeclampsia compared with the controls and in SP compared with MP supports the report of Zulfikaroğlu et al. They showed that plasma copeptin level was higher in women with preeclampsia compared to normotensive women and that a marked increase was observed with the severity of the disease. This observation could be due to activation of the neuroendocrine pathway involving the hypothalamic-pituitary-adrenal (HPA). Activation of the HPA axis by chronic psychosocial stress has been suggested as one of the mediators of the association between copeptin and preeclampsia. In addition, the observed elevated copeptin level was found to be diagnostic of preeclampsia. This observation is further supported by our observed positive correlation between copeptin and important components of preeclampsia such as SBP, DBP, proteinuria, creatinine, total bilirubin, and activities of AST and ALT in women with preeclampsia. Our observations indicate that copeptin could reliably predict preeclampsia and might be able to differentiate between MP and SP, as its concentration was higher in SP than MP. Earlier reports by Zulfikaroğlu et al. and Santillan et al. showed that copeptin is a predictive biomarker for preeclampsia, as early as the first trimester, and it might be useful in the assessment of the severity of the disease.

Preeclampsia is a major obstetric problem causing substantial maternal and perinatal morbidity and mortality worldwide, especially in developing countries. Out of the 90 women recruited for this study, 9 SP and 3 MP had abruptio placenta, but no maternal death or seizures were recorded. This suggests that abruptio placenta is more associated with SP. This has been attributed to uteroplacental insufficiency.

### Table 5: Fetal and neonatal outcomes in women with severe and mild preeclampsia, and controls

| Parameters                        | Severe preeclampsia (n=30) | Mild preeclampsia (n=30) | Control (n=30) | P     |
|-----------------------------------|-----------------------------|--------------------------|----------------|-------|
| Gestational age at delivery (days)| 232.80±10.00*              | 247.60±6.77              | 268.40±6.23   | 0.000*|
| Birth weight (kg)                 | 1.52±0.34*                  | 2.11±0.46*               | 3.47±0.31     | 0.000*|
| Infant length (m)                 | 0.41±0.03                  | 0.41±0.03                | 0.47±0.01     | 0.000*|
| Ponderal index (kg/m²)            | 29.34±7.38                 | 21.31±5.37              | 24.0±3.32     | 0.001*|
| Apgar score at 5 min              | 7.70±2.28                  | 5.83±3.03               | 9.03±1.81     | 0.000*|
| Head circumference (cm)           | 24.15±2.78                 | 26.06±2.28              | 26.06±2.28    | 0.000*|

*Significant at P<0.05 (two-tailed), †Significantly different from control, ‡Significantly different from mild preeclampsia

### Table 6: Correlation between copeptin and selected clinical and biochemical parameters, in mothers with preeclampsia

| Copeptin | r   | P     |
|----------|-----|-------|
| SBP (mmHg) | 0.67 | 0.000*|
| DBP (mmHg) | 0.40 | 0.000*|
| LOHS (days) | 0.36 | 0.000*|
| Hematuria | 0.38 | 0.000*|
| Proteinuria | 0.44 | 0.000*|
| Creatinine (mg/dl) | 0.28 | 0.030*|
| AST (IU/L) | 0.73 | 0.000*|
| ALT (IU/L) | 0.70 | 0.000*|
| Total protein (g/dl) | −0.16 | 0.240|
| Albumin (g/dl) | −0.06 | 0.630|
| Total bilirubin (mg/dl) | 0.72 | 0.000*|
| Direct bilirubin (mg/dl) | 0.22 | 0.090|

*Significant at P<0.05 (two-tailed), SBP – Systolic blood pressure; DBP – Diastolic blood pressure; LOHS – Length of hospital stay; AST – Aspartate aminotransferase; ALT – Alanine aminotransferase

### Table 7: Correlation between copeptin and fetal/neonatal outcome from neonates of mothers with preeclampsia

| Copeptin | r   | P     |
|----------|-----|-------|
| Birth weight (kg) | −0.59 | 0.000*|
| Ponderal index (kg/m²) | −0.25 | 0.050|
| Head circumference (cm) | −0.40 | 0.000*|
| Apgar score at 5 min | −0.71 | 0.000*|
| Infant length (m) | −0.48 | 0.000*|
| Infant gestational age (days) | −0.58 | 0.000*|

*Significant at P<0.05 (two-tailed)
Low birth weight and length have been associated with increased risk of chronic diseases, mortality, and hospitalizations. Similarly, 5 min Apgar score <7 has been shown to have a consistent association with neurologic disability and low cognitive function in early adulthood. In this study, there was a higher fetal death in women with preeclampsia compared with controls. A similar observation has been reported and this was attributed to the degree of hypoxia, which accompanies preeclampsia, especially when there is placental abruption which deprives the fetus of oxygen and nourishment and as a consequence, the fetus dies. The observed low birth weight, low gestational age, small infant length, low ponderal index, and small head circumference in infants of women with preeclampsia is in line with the report of Onyiriuka and Okolo. In addition, the observed significantly low Apgar score at 5 min in infants of women with preeclampsia supports the report of Kishwara et al. These poor neonatal outcomes have been attributed to uteroplacental insufficiency and inadequate transport of nutrients. These effects become more pronounced on the fetus as the pregnancy progresses and with the severity of preeclampsia, due to the inability of the uterine vasculature to keep up with the increased amount of blood and nutrients necessary for fetal development. Perhaps, this explains our observed poorer fetal/neonatal outcomes in infants of SP compared with MP. Therefore, the more SP is, the poorer the fetal/neonatal outcomes.

The observed significant negative correlation between maternal serum copeptin and some fetal/neonatal outcomes suggests that the higher the maternal serum level of copeptin, the lower the birth weight, ponderal index, head circumference, Apgar score, infant length, and infant gestational age. This inverse relationship could be due to stress-mediated HPA axis activation (regulated by AVP or copeptin), which may precipitate or induce other known humoral, vascular, immune, and morphological mechanisms of preeclampsia.

It must be noted that small sample size was a major limitation of this study. Studies with a larger population are thus desirable to confirm our findings.

It could be concluded from this study that there is elevated maternal copeptin level in preeclampsia, which increases with severity. Furthermore, copeptin level in the third trimester could predict preeclampsia and its elevation is associated with adverse perinatal outcome.

Acknowledgment
The contribution and co-operation of all the study participants and the Resident Doctors of the Departments of Obstetrics and Gynaecology and Paediatrics, University College Hospital, Ibadan, is highly appreciated.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. McLaughlin MK, Roberts JM. Hemodynamic changes. In: Lindheimer MD, Roberts JM, Cunningham FG, editors. Chesley’s Hypertensive Disorders in Pregnancy. 2nd ed. Stamford, Conn: Appleton and Lange; 1999. p. 69-102.
2. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:51-22.
3. Vanderjagt DJ, Patel RJ, El-Nafaty AU, Melah GS, Crossey MJ, Glew RH. High-density lipoprotein and homocysteine levels correlate inversely in preeclamptic women in northern Nigeria. Acta Obstet Gynecol Scand 2004;83:536-42.
4. Cunningham F, Leveno K, Bloom S, Hauth J, Gilstrap L, Wenstrom K. Williams Obstetrics. 22nd ed. New York: McGraw-Hill; 2005.
5. Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005;105:402-10.
6. Adamu YM, Salihu HM, Sathiakumar N, Alexander GR. Maternal mortality in Northern Nigeria: A population-based study. Eur J Obstet Gynecol Reprod Biol 2003;109:153-9.
7. Tukur J, Umar BA, Rabi’u A. Pattern of eclampsia in a tertiary health facility situated in a semi-rural town in Northern Nigeria. Ann Afr Med 2007;6:164-7.
8. Lim KH. Preeclampsia. Medscape. Available from: http://www.emedicine.medscape.com/article/1476919-overview#aw2aab6b3. [Last updated on 2014 Aug 05; Last cited on 2014 Sep 18].
9. Zamorski MA, Green LA. NHBPEP report on high blood pressure in pregnancy: A summary for family physicians. Am Fam Physician 2001;64:263-71.
10. Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res 2011;37:1198-202.
11. Kanayama N, el Maradny E, Kajiwara Y, Maehara K, Tokunaga N, Tero T. Hypolumbalabordosis: A predisposing factor for preeclampsia. Eur J Obstet Gynecol Reprod Biol 1997;75:115-21.
12. Singhal SR, Deepika, Anshu,Nanda S. Maternal and perinatal outcome in severe pre-eclampsia and eclampsia. South Asian Fed Obstet Gynecol 2009:1:25-8.
13. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43-9.
14. Katan M, Morgenthaler N, Widmer I, Puder J, König C, Müller B, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008;29:341-6.
15. Wellmann S, Benzing J, Fleischlin S, Morgenthaler N, Fouzas S, Bührer CA, et al. Cardiovascular biomarkers in preeclampsia at triage. Fetal Diagn Ther 2014;36:202-7.
16. Santillan M, Santillan D, Scroggins S, Min J, Leslie K, Hunter S, et al. Is preeclampsia all in the head? First-trimester prediction of preeclampsia via maternal plasma levels of the vasopressin pro-segment copeptin (860.20). The FASEB Journal 2014;28 Suppl 860.20.
17. Hauger MS, Gibbons L, Vik T, Bellizán JM. Prepregnancy weight status and the risk of adverse pregnancy outcome. Acta Obstet Gynecol Scand 2008;87:953-9.
18. Kim YH, Hwang HS, Kim YT, Kim HS, Park YW. Modulation of matrix metalloproteinase secretion by adenosine A3
receptor in preeclamptic villous explants. Reprod Sci 2008;15:939-49.
19. Jaleel A, Baseer A, Aamir S. Biochemical parameters for detection of haemolysis in pregnancy induced hypertensive women. J Coll Physicians Surg Pak 1999;9:41-2.
20. Benirschke K, Kaufmann P. The Pathology of the Human Placenta. 4th ed. New York: Springer-Verlag; 2000.
21. Morris SS, Victoria CG, Barros FC, Halpern R, Menezes AM, César JA, et al. Length and ponderal index at birth: Associations with mortality, hospitalizations, development and post-natal growth in Brazilian infants. Int J Epidemiol 1998;27:242-7.
22. Ehrenstein V, Pedersen L, Grijota M, Nielsen GL, Rothman KJ, Sørensen HT. Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts. BMC Pregnancy Childbirth 2009;9:14.
23. Onyiriuka AN, Okolo AA. Perinatal outcome in patients with preeclampsia in Benin City, Nigeria. Trop J Obstet Gynaecol 2004;21:148-52.
24. Kishwara S, Tanira S, Omar E, Wazed F, Ara S. Effects of preeclampsia on perinatal outcome. Bangladesh Med J 2011;40:33-6.
25. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:831-44.